Similar articles

• Hereditary breast-ovarian cancer: how can we use the new DNA markers to improve patient management?

  Narod S. Narod S. Clin Invest Med. 1993 Aug;16(4):314-7. Clin Invest Med. 1993. PMID: 8306541 No abstract available.
• [DNA analysis of breast cancer].

  Ohuchi N, Mori S. Ohuchi N, et al. Gan To Kagaku Ryoho. 1991 Jan;18(1):30-6. Gan To Kagaku Ryoho. 1991. PMID: 1987899 Review. Japanese.
• [Prognostic factors and markers used in urothelial carcinoma of the bladder].

  Billerey C, Vieillefond A. Billerey C, et al. Ann Pathol. 1999;19(5 Suppl):S107-9. Ann Pathol. 1999. PMID: 10599469 French. No abstract available.
• [Molecular markers of ovarian carcinoma].

  Dobryszycka W. Dobryszycka W. Postepy Hig Med Dosw. 2000;54(4):495-518. Postepy Hig Med Dosw. 2000. PMID: 11016269 Review. Polish.
• Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.

  Ottesen GL. Ottesen GL. APMIS Suppl. 2003;(108):1-67. APMIS Suppl. 2003. PMID: 12874968 Review.